SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Metrics to compare | SYNACT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYNACTPeersSector | |
---|---|---|---|---|
P/E Ratio | −13.3x | −7.3x | −0.5x | |
PEG Ratio | −0.20 | −0.09 | 0.00 | |
Price/Book | 6.0x | 4.0x | 2.6x | |
Price / LTM Sales | - | 40.2x | 3.2x | |
Upside (Analyst Target) | 16.3% | 20.8% | 43.8% | |
Fair Value Upside | Unlock | 12.9% | 5.1% | Unlock |